White matter hyperintensities (WMHs), mainly caused by cerebrovascular injury, may lead to cognitive impairment. In order to identify whether the volume of WMHs is associated with cognitive decline over years, this longitudinal study involved 818 individuals from the ADNI-2 dataset from August 2010 to May 2017. Cross-sectional and longitudinal associations of WMHs with 8 cognitive domains were explored, using Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Clinical Dementia Rating Sum of Boxes (CDRSB), Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog13), Rey Auditory Verbal Learning Test (RAVLT), Functional Assessment Questionnaire (FAQ), executive function (ADNI-EF), and memory function (ADNI-Mem). The association analyses were performed using multiple linear regression models, linear mixed models, Spearman rank correlation, and Kaplan-Meier survival curves. The volumes of WMHs were greater in patients with Alzheimer’s disease (AD) dementia compared with controls (p < 0.001) and mild cognitive impairment (p = 0.006) patients at baseline. The bigger volumes of WMHs correlated with worse performances on ADAS-Cog13 and ADNI-EF (p = 0.029; p = 0.003) at baseline and MMSE, MoCA, CDRSB, ADAS-Cog13, FAQ, and ADNI-Mem (overall p < 0.05) longitudinally, after adjusting for age, sex, educational level, apolipoprotein E ɛ4 genotype, hypertension, hyperlipidemia, diabetes, smoking, infarction, and diagnosis. Additionally, the correlations between the change rate of WMHs and change rates of MMSE, MoCA, CDRSB, FAQ, ADNI-EF, and ADNI-Mem were statistically significant. Furthermore, patients with high WMH volumes showed an increased likelihood of dementia. The results of the study suggest that WMH volume is associated with cognitive decline, and it contributes to the conversion to AD.
RizviB, NarkhedeA, LastBS, BudgeM, TostoG, ManlyJJ, SchupfN, MayeuxR, BrickmanAM (2018) The effect of white matter hyperintensities on cognition is mediated by cortical atrophy. Neurobiol Aging64, 25–32.
2.
LeeS, ViqarF, ZimmermanME, NarkhedeA, TostoG, BenzingerTL, MarcusDS, FaganAM, GoateA, FoxNC, CairnsNJ, HoltzmanDM, BucklesV, GhettiB, McDadeE, MartinsRN, SaykinAJ, MastersCL, RingmanJM, RyanNS, ForsterS, LaskeC, SchofieldPR, SperlingRA, SallowayS, CorreiaS, JackCJr., WeinerM, BatemanRJ, MorrisJC, MayeuxR, BrickmanAM, Dominantly Inherited Alzheimer Network (2016) White matter hyperintensities are a core feature of Alzheimer’s disease: Evidence from the dominantly inherited Alzheimer network. Ann Neurol79, 929–939.
3.
BosD, WoltersFJ, DarweeshSKL, VernooijMW, de WolfF, IkramMA, HofmanA (2018) Cerebral small vessel disease and the risk of dementia: A systematic review and meta-analysis of population-based evidence. Alzheimers Dement14, 1482–1492.
4.
McAleeseKE, WalkerL, GrahamS, MoyaELJ, JohnsonM, ErskineD, CollobySJ, DeyM, Martin-RuizC, TaylorJP, ThomasAJ, McKeithIG, De CarliC, AttemsJ (2017) Parietal white matter lesions in Alzheimer’s disease are associated with cortical neurodegenerative pathology, but not with small vessel disease. Acta Neuropathol134, 459–473.
5.
EnglundE (1998) Neuropathology of white matter changes in Alzheimer’s disease and vascular dementia. Dement Geriatr Cogn Disord9 Suppl 1, 6–12.
6.
SarroL, TosakulwongN, SchwarzCG, Graff-RadfordJ, PrzybelskiSA, LesnickTG, ZukSM, ReidRI, RamanMR, BoeveBF, FermanTJ, KnopmanDS, ComiG, FilippiM, MurrayME, ParisiJE, DicksonDW, PetersenRC, JackCRJr., KantarciK (2017) An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer’s disease. Alzheimers Dement13, 257–266.
7.
BlennowK, ZetterbergH, PerryG, AvilaJ, TabatonM, ZhuX (2018) The past and the future of Alzheimer’s disease fluid biomarkers. J Alzheimers Dis62, 1125–1140.
8.
LaforceRJr., SoucyJP, SellamiL, Dallaire-TherouxC, BrunetF, BergeronD, MillerBL, OssenkoppeleR (2018) Molecular imaging in dementia: Past, present, and future. Alzheimers Dement14, 1522–1552.
9.
PrabhakaranS (2019) Blood pressure, brain volume and white matter hyperintensities, and dementia risk. JAMA322, 512–513.
10.
SmithCD, SnowdonDA, WangH, MarkesberyWR (2000) White matter volumes and periventricular white matter hyperintensities in aging and dementia. Neurology54, 838–842.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34, 939–944.
FolsteinMF, FolsteinSE, McHughPR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
15.
NasreddineZS, PhillipsNA, BedirianV, CharbonneauS, WhiteheadV, CollinI, CummingsJL, ChertkowH (2005) The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc53, 695–699.
16.
MorrisJC (1993) The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology43, 2412–2414.
17.
RosenWG, MohsRC, DavisKL (1984) A new rating scale for Alzheimer’s disease. Am J Psychiatry141, 1356–1364.
18.
SchmidtM (1996) Rey Auditory Verbal Learning Test: A Handbook. Western Psychological Services, Los Angeles, CA.
19.
PfefferRI, KurosakiTT, HarrahCHJr., ChanceJM, FilosS (1982) Measurement of functional activities in older adults in the community. J Gerontol37, 323–329.
20.
GibbonsLE, CarleAC, MackinRS, HarveyD, MukherjeeS, InselP, CurtisSM, MungasD, CranePK, Alzheimer’s Disease Neuroimaging Initiative (2012) A composite score for executive functioning, validated in Alzheimer’s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav6, 517–527.
21.
CranePK, CarleA, GibbonsLE, InselP, MackinRS, GrossA, JonesRN, MukherjeeS, CurtisSM, HarveyD, WeinerM, MungasD, Alzheimer’s Disease Neuroimaging Initiative (2012) Development and assessment of a composite score for memory in the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav6, 502–516.
22.
SachdevPS, ZhuangL, BraidyN, WenW (2013) Is Alzheimer’s a disease of the white matter?Curr Opin Psychiatry26, 244–251.
SmithEE, EgorovaS, BlackerD, KillianyRJ, MuzikanskyA, DickersonBC, TanziRE, AlbertMS, GreenbergSM, GuttmannCR (2008) Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia. Arch Neurol65, 94–100.
26.
BoylePA, YuL, FleischmanDA, LeurgansS, YangJ, WilsonRS, SchneiderJA, ArvanitakisZ, ArfanakisK, BennettDA (2016) White matter hyperintensities, incident mild cognitive impairment, and cognitive decline in old age. Ann Clin Transl Neurol3, 791–800.
27.
PrinsND, van StraatenEC, van DijkEJ, SimoniM, van SchijndelRA, VroomanHA, KoudstaalPJ, ScheltensP, BretelerMM, BarkhofF (2004) Measuring progression of cerebral white matter lesions on MRI: visual rating and volumetrics. Neurology62, 1533–1539.
28.
LiuY, ZhangM, BaoH, ZhangZ, MeiY, YunW, ZhouX (2018) The efficacy of intravenous thrombolysis in acute ischemic stroke patients with white matter hyperintensity. Brain Behav8, e01149.
29.
PrinsND, ScheltensP (2015) White matter hyperintensities, cognitive impairment and dementia: an update. Nat Rev Neurol11, 157–165.
30.
BoctiC, SwartzRH, GaoFQ, SahlasDJ, BehlP, BlackSE (2005) A new visual rating scale to assess strategic white matter hyperintensities within cholinergic pathways in dementia. Stroke36, 2126–2131.
31.
CoxSR, LyallDM, RitchieSJ, BastinME, HarrisMA, BuchananCR, Fawns-RitchieC, BarbuMC, de NooijL, ReusLM, AllozaC, ShenX, NeilsonE, AldersonHL, HunterS, LiewaldDC, WhalleyHC, McIntoshAM, LawrieSJ, PellJP, Tucker-DrobEM, WardlawJM, GaleCR, DearyIJ (2019) Associations between vascular risk factors and brain MRI indices in UK Biobank. Eur Heart J40, 2290–2300.
